Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
ALN-VSP
Also known as: formerly ALN-VSP01
print preview
bookmark
share with colleague
General Information
Company
Alnylam Pharmaceuticals Inc.
Description
RNA therapeutic targeting kinesin spindle protein (KSP) and VEGF genes
Molecular Target
Vascular endothelial growth factor (VEGF)
;
Kinesin spindle protein (KSP) (Eg5) (TRIP5)
Mechanism of Action
Gene silencing
Latest Stage of Development
Phase I
Indication
Liver cancer
Partner
Ascletis Pharmaceuticals Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy